Express Mail Label No. EL 565228948US

Date of Deposit: October 4, 2001

Attorney Docket No. 21272-048CIP2C (Formerly 790CIP2C)

# OCT 0 4 **2001**

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Y. Tom Tang et al.

DEMPO

Hyseq, Inc.

. .

SERIAL NUMBER:

09/728,711

EXAMINER:

Not Yet Assigned

FILING DATE:

November 30, 2000

ART UNIT:

1645

FOR:

Novel Nucleic Acids and Polypeptides

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

# REQUEST FOR CORRECTED FILING RECEIPT

- Applicants request a Corrected Filing Receipt for the above-mentioned patent application. Applicants
  enclose a copy of the Filing Receipt with the corrections noted thereon. Issuance of a corrected filing
  receipt is respectfully requested.
- 2. There are errors with respect to the following data, which are:

 $\boxtimes$ 

omitted.

#### Error in

1. Applicants' names

### Correct data

Y. Tom Yang, San Jose, CA; Chenghua Liu, San Jose, CA; Ping Zhou, Cupertino, CA; Vinod Asundi, Foster City, CA; Feiyan Ren, Cupertino, CA; Jie Zhang, Campbell, CA; Qing A. Zhao, San Jose, CA; Aidong J. Zue, Sunnyvale, CA; Ryle Goodrich, San Jose, CA; Tom Wehrman, Stanford, CA; Radoje T. Drmanac, Palo Alto, CA;

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529


Cynthia A. Kozakiewicz, Reg. No. 42764

Attorneys for Applicants c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING DATE

GRP ART UNIT

FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS

790CIP2C

TOT CLAIMS

IND CLAIMS

09/728,711

11/30/2000

1645

580

21272-048CIP2C

Leslie A. Mooi

Hyseq Inc 670 Alamanor Avenue Sunnyvale, CA 94085

\*OC000000005874942\*

Date Mailed: 03/19/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

San Jose, CA; Cherghua Liu, a...

Y. Tom Tang, Residence Not Provided;

Vinod Asundi, Foster City, CA; Feiyan Ren, Cupertno, CA; Jie Zhang, Campell,

Continuing Data as Claimed by Applicant Qing A. Zhao, San Jose CA; Aidong J. Zue, Sunnyvale, CA.

THIS APPLICATION IS A CIP OF 09/649,167 08/23/2000

Ryle Goodneh, San Jose CA;

WHICH IS A CIP OF 09/540,217\*

Tom Wehrman, Stanford, CA;

Radoje T. Drmanac, Pallo Alto,

**Foreign Applications** 

If Required, Foreign Filing License Granted 03/16/2001

\*\* SMALL ENTITY \*\*

Title

Novel nucleic acids and polypeptides

**Preliminary Class** 

435

Data entry by: JONES, ANGELONA

Team: 3700

AUG 0 9 2001

. 3 MARIJA BYRO (BINI 1974) BYRO KIRIK BUKA 1984 BURA KIRIK KIRIK BINI KIRIK KIRIK BUKA KIRIK BINI KIRIK BUKA K

MINTZ LEVIN, BOSTON PATENT DOCKET DEPT.



#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

# PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231 Express Mail Label No. EL 585228948US

Date of Deposit: October 4, 2001

Attorney Docket No. 21272-048CIP2C (Formerly 790CIP2C)



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Y. Tom Tang et al.

SAABK OX

Hyseq, Inc.

SERIAL NUMBER:

00/700 711

09/728,711

EXAMINER:

Not Yet Assigned

FILING DATE:

November 30, 2000

ART UNIT:

1645

FOR:

Novel Nucleic Acids and Polypeptides

Assistant Commissioner for Patents Washington, D.C. 20231

# **CHANGE OF ATTORNEY DOCKET NUMBER**

Please note that the Attorney Docket Number has been changed from 790CIP2C to 21272-048CIP2C. Please reference 21272-048CIP2C on all future correspondence.

Respectfully submitted,

Ivor R. Elriffi, Reg. No. 39,529

Cynthia A. Kozakiewicz, Reg. No. 42764

Attorneys for Applicants c/o MINTZ, LEVIN

One Financial Center Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

TRA 1572176v1